BIO Quote, Financials, Valuation and Earnings

Azenta, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -3.49%. Bio-Rad Laboratories, Inc.'s return on equity of 10.99% beat Azenta, Inc.'s return on equity of 1.7%.

Bio-Rad Laboratories, Inc. has a consensus price target of $321.25, signalling upside risk potential of 14.74%. On the other hand Azenta, Inc. has an analysts' consensus of $37.83 which suggests that it could grow by 70.87%. Given that Azenta, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Azenta, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.156, which suggesting that the stock is 15.649% more volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.466, suggesting its more volatile than the S&P 500 by 46.569%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta, Inc. offers a yield of 1.65% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend.

Bio-Rad Laboratories, Inc. quarterly revenues are $693.2M, which are larger than Azenta, Inc. quarterly revenues of $148.6M. Bio-Rad Laboratories, Inc.'s net income of $720M is higher than Azenta, Inc.'s net income of -$5.2M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 10.09x while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 2.97x versus 1.86x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bionano Genomics, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -99.77%. Bio-Rad Laboratories, Inc.'s return on equity of 10.99% beat Bionano Genomics, Inc.'s return on equity of -59.14%.

Bio-Rad Laboratories, Inc. has a consensus price target of $321.25, signalling upside risk potential of 14.74%. On the other hand Bionano Genomics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 358.33%. Given that Bionano Genomics, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Bionano Genomics, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.156, which suggesting that the stock is 15.649% more volatile than S&P 500. In comparison Bionano Genomics, Inc. has a beta of 1.603, suggesting its more volatile than the S&P 500 by 60.334%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bionano Genomics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bionano Genomics, Inc. pays out -- of its earnings as a dividend.

Bio-Rad Laboratories, Inc. quarterly revenues are $693.2M, which are larger than Bionano Genomics, Inc. quarterly revenues of $8M. Bio-Rad Laboratories, Inc.'s net income of $720M is higher than Bionano Genomics, Inc.'s net income of -$7.9M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 10.09x while Bionano Genomics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 2.97x versus 0.23x for Bionano Genomics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of 2.99%. Bio-Rad Laboratories, Inc.'s return on equity of 10.99% beat Bruker Corp.'s return on equity of -0.39%.

Bio-Rad Laboratories, Inc. has a consensus price target of $321.25, signalling upside risk potential of 14.74%. On the other hand Bruker Corp. has an analysts' consensus of $47.86 which suggests that it could grow by 30.19%. Given that Bruker Corp. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Bruker Corp. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.156, which suggesting that the stock is 15.649% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.201, suggesting its more volatile than the S&P 500 by 20.087%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker Corp. offers a yield of 0.53% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Bruker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bio-Rad Laboratories, Inc. quarterly revenues are $693.2M, which are smaller than Bruker Corp. quarterly revenues of $977.2M. Bio-Rad Laboratories, Inc.'s net income of $720M is higher than Bruker Corp.'s net income of $29.2M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 10.09x while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 2.97x versus 1.66x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of -52.36% compared to Bio-Rad Laboratories, Inc.'s net margin of -12%. Bio-Rad Laboratories, Inc.'s return on equity of 10.99% beat Harvard Bioscience, Inc.'s return on equity of -232.93%.

Bio-Rad Laboratories, Inc. has a consensus price target of $321.25, signalling upside risk potential of 14.74%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $6.00 which suggests that it could grow by 15.39%. Given that Harvard Bioscience, Inc. has higher upside potential than Bio-Rad Laboratories, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Bio-Rad Laboratories, Inc..

Bio-Rad Laboratories, Inc. has a beta of 1.156, which suggesting that the stock is 15.649% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.498, suggesting its more volatile than the S&P 500 by 49.848%.

Bio-Rad Laboratories, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories, Inc. pays -- of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend.

Bio-Rad Laboratories, Inc. quarterly revenues are $693.2M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $23.7M. Bio-Rad Laboratories, Inc.'s net income of $720M is higher than Harvard Bioscience, Inc.'s net income of -$2.8M. Notably, Bio-Rad Laboratories, Inc.'s price-to-earnings ratio is 10.09x while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories, Inc. is 2.97x versus 0.88x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.